Literature DB >> 11781690

Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms.

A Hoy1, D Trégouët, B Leininger-Muller, O Poirier, M Maurice, C Sass, G Siest, L Tiret, S Visvikis.   

Abstract

Myeloperoxidase (MPO) has been involved in the pathogenesis of several diseases through excessive production of reactive oxygen species (ROS) as well as through its genetic polymorphism. The aims of this study were to identify the factors affecting MPO serum concentration, to study the familial resemblance of MPO levels and to investigate the association between newly described MPO polymorphisms as well as the G-463A one and MPO levels in a healthy population. MPO serum concentrations were measured by an enzymatic immuno-assay (EIA) in 82 healthy families of the STANISLAS Cohort and MPO genotype, determination was performed using PCR-restriction fragment length polymorphism or allele specific oligonucleotide assay. MPO concentrations were significantly higher in parents than in offspring. The factors affecting MPO levels were age, the number of white cells, smoking in fathers and oral contraceptive intake in mothers. They explain from 12.4% up to 35.9% of MPO variability in men and women, respectively. Family correlations of MPO concentrations were of similar magnitude. The -129A allele of a newly described G-129A substitution was significantly associated with decreased MPO levels, whereas the -463A allele was suggested to be associated with increased levels of lipid variables. In this study, we identified factors affecting MPO serum concentrations and showed that molecular variations of the gene have only a weak influence on MPO variability. In contrast, the association between the G-463A polymorphism and lipid levels would suggest a possible implication of MPO in the risk of cardiovascular diseases. These results have to be confirmed and further investigations will be conducted in that way.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781690     DOI: 10.1038/sj.ejhg.5200702

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  23 in total

1.  Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Authors:  Richard A Maki; Michael Holzer; Khatereh Motamedchaboki; Ernst Malle; Eliezer Masliah; Gunther Marsche; Wanda F Reynolds
Journal:  Free Radic Biol Med       Date:  2019-06-06       Impact factor: 7.376

2.  Neutrophil-Derived Myeloperoxidase Facilitates Both the Induction and Elicitation Phases of Contact Hypersensitivity.

Authors:  Anna Strzepa; Cody J Gurski; Landon J Dittel; Marian Szczepanik; Kirkwood A Pritchard; Bonnie N Dittel
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

3.  Genome-wide and gene-centric analyses of circulating myeloperoxidase levels in the charge and care consortia.

Authors:  Alexander P Reiner; Jaana Hartiala; Tanja Zeller; Joshua C Bis; Josée Dupuis; Myriam Fornage; Jens Baumert; Marcus E Kleber; Philipp S Wild; Stephan Baldus; Suzette J Bielinski; João D Fontes; Thomas Illig; Brendan J Keating; Leslie A Lange; Francisco Ojeda; Martina Müller-Nurasyid; Thomas F Munzel; Bruce M Psaty; Kenneth Rice; Jerome I Rotter; Renate B Schnabel; W H Wilson Tang; Barbara Thorand; Jeanette Erdmann; David R Jacobs; James G Wilson; Wolfgang Koenig; Russell P Tracy; Stefan Blankenberg; Winfried März; Myron D Gross; Emelia J Benjamin; Stanley L Hazen; Hooman Allayee
Journal:  Hum Mol Genet       Date:  2013-04-24       Impact factor: 6.150

4.  Effects of myeloperoxidase -463 G/A gene polymorphism and plasma levels on coronary artery disease.

Authors:  Arzu Ergen; Selim İsbir; Özlem Timirci; Atike Tekeli; Turgay İsbir
Journal:  Mol Biol Rep       Date:  2010-06-22       Impact factor: 2.316

5.  Serum malondialdehyde levels, myeloperoxidase and catalase activities in patients with nephrotic syndrome.

Authors:  Huseyin Begenik; Yasemin Usul Soyoral; Reha Erkoc; Habib Emre; Abdullah Taskın; Mehmet Tasdemir; Mehmet Aslan
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

Review 6.  Myeloperoxidase: A new player in autoimmunity.

Authors:  Anna Strzepa; Kirkwood A Pritchard; Bonnie N Dittel
Journal:  Cell Immunol       Date:  2017-05-10       Impact factor: 4.868

7.  Inactivation of anthracyclines by serum heme proteins.

Authors:  Brett A Wagner; Lynn M Teesch; Garry R Buettner; Bradley E Britigan; C Patrick Burns; Krzysztof J Reszka
Journal:  Chem Res Toxicol       Date:  2007-05-12       Impact factor: 3.739

8.  Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus.

Authors:  Henda Bouali; Paul Nietert; Tamara M Nowling; Janardan Pandey; Mary Anne Dooley; Glinda Cooper; John Harley; Diane L Kamen; Jim Oates; Gary Gilkeson
Journal:  J Rheumatol       Date:  2007-09-15       Impact factor: 4.666

Review 9.  Myeloperoxidase: a target for new drug development?

Authors:  E Malle; P G Furtmüller; W Sattler; C Obinger
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

10.  Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease.

Authors:  Lukas Kubala; Guijing Lu; Stephan Baldus; Lars Berglund; Jason P Eiserich
Journal:  Clin Chim Acta       Date:  2008-04-08       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.